ProjectBI 1516-0003 – a phase Ib, multicentre, randomised, double-blind, placebo-controlled 2 sequence crossover trial to…

Basic data

Acronym:
BI 1516-0003
Title:
a phase Ib, multicentre, randomised, double-blind, placebo-controlled 2 sequence crossover trial to evaluate the effects of BI 3031185 on safety, tolerabilityy, pharmcodynamics, and pharmocokinetics in patients with borderline personality disorder (BPD) or attention-deficit hyperactivity disorder (ADHD)
Duration:
01/01/2027 to 29/02/2028
Abstract / short description:
the main objective of the trial is to assess safety and tolerability of a single dose of BI 3031185 in participants with BPD or ADHD

Involved staff

Managers

Faculty of Medicine
University of Tübingen
Department of Psychiatry and Psychotherapy
Hospitals and clinical institutes, Faculty of Medicine
Department of Psychiatry and Psychotherapy
Hospitals and clinical institutes, Faculty of Medicine

Other staff

Department of Psychiatry and Psychotherapy
Hospitals and clinical institutes, Faculty of Medicine
Department of Psychiatry and Psychotherapy
Hospitals and clinical institutes, Faculty of Medicine
Department of Psychiatry and Psychotherapy
Hospitals and clinical institutes, Faculty of Medicine
Department of Psychology
Faculty of Science
Department of Psychiatry and Psychotherapy
Hospitals and clinical institutes, Faculty of Medicine
Department of Psychiatry and Psychotherapy
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of General psychiatry and psychotherapy with outpatient clinic
Department of Psychiatry and Psychotherapy
Hospitals and clinical institutes, Faculty of Medicine

Funders

Ingelheim am Rhein, Rheinland-Pfalz, Germany
Help

will be deleted permanently. This cannot be undone.